NCT05428449View on ClinicalTrials.gov

Study in Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of GT20029

PHASE1CompletedINTERVENTIONAL
Enrollment

123

Participants

Timeline

Start Date

February 10, 2022

Primary Completion Date

October 27, 2022

Study Completion Date

April 6, 2023

Conditions
Androgenetic AlopeciaAcne Vulgaris
Interventions
DRUG

GT20029 Gel

Stage 1: One single dose Stage 2: One single dose per day (QD) or twice a day (BID) treatment over 14-day period

DRUG

GT20029 Gel Placebo

Stage 1: One single dose Stage 2: One single dose per day (QD) or twice a day (BID) treatment over 14-day period

Trial Locations (2)

84107

JBR Clinical Research Sharp, Salt Lake City

91942

Velocity San Diego, San Diego

All Listed Sponsors
lead

Suzhou Kintor Pharmaceutical Inc,

INDUSTRY